Advertisement
Mayo Clinic Proceedings Home

Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products

  • Sanket S. Dhruva
    Correspondence
    Correspondence: Address to Sanket S. Dhruva, MD, MHS, San Francisco VA Medical Center, 4150 Clement St, 2A-18, San Francisco, CA 94121.
    Affiliations
    Department of Medicine, San Francisco Veterans Affairs Health Care System, and University of California, San Francisco, School of Medicine
    Search for articles by this author
  • Nilay D. Shah
    Affiliations
    Division of Health Care Policy and Research and Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN
    Search for articles by this author
  • Joseph S. Ross
    Affiliations
    Section of General Internal Medicine and National Clinician Scholars Program, Yale School of Medicine, New Haven, CT

    Department of Health Policy and Management, Yale School of Public Health, New Haven, CT

    Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
    Search for articles by this author
Published:October 21, 2020DOI:https://doi.org/10.1016/j.mayocp.2020.04.013
      In June 2017, the Food and Drug Administration (FDA) approved a new indication for use of the Edwards Sapien 3 transcatheter heart valve (Edwards Lifesciences, Irvine, California), 2 years after the initial approval of the device. This approval was unique because the underlying evidence was generated from a postmarket registry of patients receiving transcatheter aortic valve replacement, not from premarket clinical trials. Registries, along with electronic health records (EHRs) and claims data, are among the many data sources generated outside of traditional clinical research settings being used for real-world evidence (RWE).
      • Sherman R.E.
      • Anderson S.A.
      • Dal Pan G.J.
      • et al.
      Real-world evidence: what is it and what can it tell us?.
      Such RWE-based approvals represent not only the future of generating evidence of the benefits and risks of medical products to inform regulatory approvals, but also decisions by payers, patients, and clinicians. Accordingly, to ensure that this evidence is rigorous and reliable, steps must be taken to require registration and results reporting of all RWE studies of FDA-regulated products.

      Abbreviations and Acronyms:

      CDRH (Center for Devices and Radiologic Health), EHR (electronic health records), FDA (Food and Drug Administration), ICMJE (International Committee of Medical Journal Editors), OHDSI (Observational Health Data Science Initiative), RWE (real-world evidence)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sherman R.E.
        • Anderson S.A.
        • Dal Pan G.J.
        • et al.
        Real-world evidence: what is it and what can it tell us?.
        N Engl J Med. 2016; 375: 2293-2297
        • Berger M.L.
        • Sox H.
        • Willke R.J.
        • et al.
        Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
        Pharmacoepidemiol Drug Saf. 2017; 26: 1033-1039
        • Wang S.V.
        • Schneeweiss S.
        • Berger M.L.
        • et al.
        • Joint ISPE-ISPOR Special Task Force on Real-World Evidence in Health Care Decision Making
        Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0.
        Pharmacoepidemiol Drug Saf. 2017; 26: 1018-1032
        • Zarin D.A.
        • Crown W.H.
        • Bierer B.E.
        Issues in the registration of database studies.
        J Clin Epidemiol. 2020; 121: 29-31
        • Food & Drug Administration
        Framework for FDA's Real-World Evidence Program.
        December 2018
        • Dwan K.
        • Gamble C.
        • Williamson P.R.
        • Kirkham J.J.
        Systematic review of the empirical evidence of study publication bias and outcome reporting bias: an updated review.
        PLoS One. 2013; 8: e66844
        • Phillips A.T.
        • Desai N.R.
        • Krumholz H.M.
        • Zou C.X.
        • Miller J.E.
        • Ross J.S.
        Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
        Trials. 2017; 18: 333
        • Krumholz H.M.
        • Ross J.S.
        • Otto C.M.
        Will research preprints improve healthcare for patients?.
        BMJ. 2018; 362: k3628
        • von Elm E.
        • Altman D.G.
        • Egger M.
        • Pocock S.J.
        • Gotzsche P.C.
        • Vandenbroucke J.P.
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
        Ann Intern Med. 2007; 147: 573-577
        • Schuemie M.J.
        • Ryan P.B.
        • Pratt N.
        • et al.
        Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND).
        J Am Med Inform Assoc. 2020; 27: 1331-1337